Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16769802 | 0.94 | CYP1A2 (0.30) | CYP1A2GAACYP2C19L3MBTL1 | |
| SCHEMBL16628599 | 0.86 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL975684 | 0.84 | SLC29A1 (0.34) | SMN1; SMN2CA1CA2CA9SLC29A1 | |
| SCHEMBL16628588 | 0.84 | KCNH3 (0.33) | CYP1A2CYP2C19CA1CA2CA9 | |
| SCHEMBL16628597 | 0.84 | KCNH3 (0.33) | CYP1A2CYP2C19CA1CA2CA9 | |
| SCHEMBL20740706 | 0.82 | SLC29A1 (0.39) | SMN1; SMN2CA1CA2CA9SLC29A1 | |
| SCHEMBL23327153 | 0.82 | SLC29A1 (0.33) | SMN1; SMN2SLC29A1 | |
| SCHEMBL20740721 | 0.82 | DNM2 (0.41) | SMN1; SMN2SLC29A1 | |
| SCHEMBL20656540 | 0.81 | KMT2A (0.38) | CYP1A2CYP2C19CA1CA2CA9 | |
| SCHEMBL20656497 | 0.81 | KMT2A (0.38) | CYP1A2CYP2C19CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2859962-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2019-01-23 | — | — | EP | claimed |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | claimed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2859962-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-04-15 | — | — | EP | claimed |
| US-11440304-B2 | Laminate and its production method | AGC Inc. (JP) | 2022-09-13 | — | — | US | disclosed |
| CN-111050929-B | Laminate and method for producing same | ＡＧＣ株式会社 | 2022-07-22 | — | — | CN | disclosed |
| EP-3505522-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-20200164625-A1 | LAMINATE AND ITS PRODUCTION METHOD | AGC Inc. (JP) | 2020-05-28 | — | — | US | disclosed |
| US-10385076-B2 | Surface treatment agent and novel compound | Mori, Kunio (JP) | 2019-08-20 | — | — | US | disclosed |
| EP-3505522-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-2859962-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9790242-B2 | Surface treatment method, surface treatment agent, and novel compound | Mori, Kunio (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2859962-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | EPCAM, ITGAM, MET | CYP1A2 1014/4885GAA 1082/4885CYP2C19 2319/4885 |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | EPCAM, MET, ITGAM | CYP1A2 2298/4885GAA 645/4885CYP2C19 4298/4885 |
| US-10385076-B2 | Surface treatment agent and novel compound | EPCAM, MET, ITGAM | CYP1A2 2298/4885GAA 645/4885CYP2C19 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.